FRAB0303 | ACCEPTABILITY AND PREFERENCES OF LONG-ACTING HIV TREATMENT OPTIONS AMONG ADOLESCENTS AND YOUNG ADULTS LIVING WITH HIV IN KENYA

Joan Keke, Lynda Oluoch, Paul Mwangi, Jane Gacheru, Kenneth Ngure | Kenya

Adherence to the current regimen of oral antiretroviral therapy (ART) is a challenge, especially among adolescents and young adults (AYA) in sub-Saharan Africa due to pill burden. The advancement of long-acting treatment options has the potential to address some of these challenges. However, little is known about the preferences of specific formulations. We conducted descriptive research to evaluate acceptability and preferences for LA ART products. We conducted quantitative surveys during participants’ last study visit in a study assessing effectiveness and B cell response to the Quadrivalent HPV vaccine 9 years post-vaccination. We assessed the hypothetical acceptability and preferences of four long-acting HIV treatments currently under development. (injectables [2, 3, 6, and 12 monthly], implants [3, 6, 12 monthly], and oral pills [weekly and monthly]) focusing on their interest, preferred dosage, packaging, visit schedule, access points, and concerns while using the preferred formulation. Data was analyzed descriptively. AYA aged 18-24 years living with HIV who came for their exit visit were eligible for the survey. Between July and November 2023, we conducted surveys with 150 AYAs; the median age was 22 years (IQR 21–23), about half (52.9%) were females, 84 (54.2%) had completed their secondary school education and 91 (58.7%) were not financially independent. The most preferred ART formulation was injection (71.6%), followed by oral pills (17.4%) and implants (10.3%). Most AYAs preferred a yearly frequency for injectables 48.4%, implants 42.5% and monthly oral pills 76.8%. Aspects for the most preferred ART formulation included ease of use 21.3%, dosage frequency 41.3%, perceived effectiveness in treating HIV 69.7%, privacy/discreetness 54.8%, and ease of access 84.5%. For packaging, most (64.5%) preferred blister packs for oral pills. Most (87.1%) AYAs reported, their preferred access point for long-acting ART products was at HIV clinics. Most AYA (44.5%) were concerned about the safety of the LA ART. Our findings indicate that injectable long-acting HIV treatments with extended duration are highly preferred among AYA living with HIV. However, safety remains a critical concern for this population. Prioritizing the availability of long-acting treatments could enhance treatment options and support adherence, ultimately improving health outcomes.